PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Min Zhang	06/15/2010

RECEIVING PARTY DATA

Name:	Abbott Laboratories	
Street Address:	100 Abbott Park Road	
Internal Address:	Dept. 377 AP6A	
City:	Abbott Park	
State/Country:	ILLINOIS	
Postal Code:	60064-6008	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	12769878

CORRESPONDENCE DATA

Fax Number: (312)819-1910

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 312-819-1900

Email: jwiggins@polsinelli.com

Correspondent Name: Lisa V. Mueller/Polsinelli Shughart PC

Address Line 1: 161 N. Clark Street

Address Line 2: Suite 4200

Address Line 4: Chicago, ILLINOIS 60601

ATTORNEY DOCKET NUMBER:	9923USO1
NAME OF SUBMITTER:	Lisa V. Mueller

Total Attachments: 2

source=Executed_Assignment#page1.tif source=Executed_Assignment#page2.tif

PATENT REEL: 024679 FRAME: 0135

501231472

T \$40.00

ASSIGNMENT

WHEREAS, Min ZHANG; hereinafter called the "Assignor" have made the invention described in the United States patent application entitled "BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR" that has a U.S. Patent Application Serial Number of 12/769,878 filed on April 29, 2010;

WHEREAS, Abbott Laboratories, a corporation, having a place of business at 100 Abbott Park Road, Dept. 377 AP6A, Abbott Park, Illinois 60064-6008, hereinafter called the "Assignee", desires to acquire the entire right, title and interesting and to the invention and to the patent application identified above, and all patents, foreign and domestic, which may be obtained for said invention, as set forth below.

NOW THEREFORE, in exchange for valuable and legally sufficient consideration, the Assignor has sold, assigned and transferred, and by these presents do sell, assign and transfer to the Assignee, the entire right, title and interest for the United States and elsewhere in and to the invention and the patent application identified above, and any patents that may issue for said invention in the United States and elsewhere; together with the entire right, title and interest in and to said invention and all patent applications, patents, utility models and designs therefore in all countries foreign to the United, including the full right to claim for any such application all benefits and priority rights under any applicable convention; together with the entire right, title and interest in and to all continuations, divisions, renewals and extensions of any of the patent applications, patents, utility models and designs defined above; to have and to hold for sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents.

The Assignor hereby covenant and agree, for both the Assignor and Assignor's legal representative, that Assignor has the full right to convey the interest assigned by this Assignment; and that the Assignor will assist the Assignee in the prosecution of the patent applications identified above, in the making and prosecution of any other applications that the Assignee like exclusive title in and to all such other patent applications and patents, in the prosecution of any interference which may arise involving said invention, or any such patent application or patent, and in assisting Assignee in enforcement of any rights arising out of the Assignment; and that the Assignors will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignee to carry out the terms of this Agreement.

The Commissioner of Patents and Trademarks is hereby authorized and requested to issue patents to the Assignee in accordance with the terms of this Assignment.

PATENT REEL: 024679 FRAME: 0136 IN TESTIMONY WHEREOF, THE Assignor has executed this agreement.

DATED: 6-15-20%

RECORDED: 07/01/2010

Min ZHANG

PATENT REEL: 024679 FRAME: 0137